The global asthma drugs market size was estimated to be US$ 23.32 Billion in 2022 and is expected grow at a CAGR of 5.6% between 2023 to 2032.
Asthma is a chronic respiratory condition that affects the airways, making it difficult to breathe. The airways become inflamed, narrowed and produce extra mucus, causing shortness of breath, wheezing, chest tightness and coughing. It is a common condition that affects people of all ages and can range from mild to severe.
The major treatment options for asthma include medications, lifestyle changes and avoiding triggers. Medications are the most important aspect of asthma treatment, and there are several types that are used to control symptoms, prevent asthma attacks and improve lung function. The most commonly used medications include bronchodilators, corticosteroids, and combination inhaled steroids and bronchodilators.
Drugs are very helpful in treating asthma by reducing the inflammation in the airways, making it easier to breathe. Bronchodilators, for example, relax the muscles in the airways, making it easier for air to flow through. Corticosteroids reduce inflammation in the airways and help to prevent asthma attacks. Inhaled corticosteroids are the most commonly used type and are often used long-term to control symptoms and prevent asthma attacks.
The global asthma drug market is driven by the increasing prevalence of asthma, technological advancements in asthma treatment, growing awareness about asthma, and increasing government support. The growing number of asthma patients is driving demand for effective asthma drugs, while technological advancements have led to the development of more efficient and effective drugs.
Increased public awareness and government support are also driving market growth. The introduction of biologics and monoclonal antibodies has provided new treatment options for patients with severe asthma, and governments around the world are taking steps to support the development of new asthma drugs and increase access to treatment.
On the basis of drug type, the market is segmented into Bronchodilators, Corticosteroids, Leukotriene modifiers, Methylxanthines, and Immune system modulators. Among these segments, the corticosteroids segment is the fastest-growing segment of the global asthma drug market.
This is due to several factors, including the effectiveness of corticosteroids in reducing airway inflammation and improving lung function, as well as their long-term safety and efficacy profiles. Corticosteroids are widely used as first-line therapy for patients with moderate to severe asthma and are also used in combination with other drugs, such as bronchodilators, to provide effective treatment.
The bronchodilators segment is also a significant contributor to the market, driven by the effectiveness of these drugs in relieving airway obstruction and improving lung function. Bronchodilators, such as beta-2 agonists and anticholinergics, are widely used as first-line therapy for mild to moderate asthma and are also used in combination with corticosteroids for more severe asthma.
The leukotriene modifiers segment is also growing, driven by the increasing use of these drugs as an alternative to corticosteroids for the treatment of asthma. Leukotriene modifiers, such as montelukast and zafirlukast, target specific cytokines that drive asthma, leading to improved control of asthma symptoms.
On the basis of mode of administration, the market is segmented into Tablets and Capsules, Liquids, Inhalers, Injections, and Sprays and Powders. Amongst these segments, inhaler segment is the largest.
While, the fastest-growing segment in the market is the liquid segment. This is due to the increasing demand for liquid formulations, particularly for children and elderly patients who may have difficulty swallowing pills or using inhalers. Liquid formulations are also becoming more popular due to the growing trend of alternative medicine, with patients seeking more natural and holistic treatments.
Regionally, the global asthma drugs market covers, North America, Europe, Asia Pacific, Middle East and Africa, and South America. Among these segments, North America is the largest segment closely followed by Europe. While, the fastest-growing market for asthma drugs is the Asia Pacific region, due to the increasing prevalence of asthma and the growing awareness about the availability of treatments in countries such as China, India, and Japan.
In addition, the growing economic development in the region is driving the growth of the healthcare sector, with increased spending on healthcare and a greater availability of advanced treatments. The increasing focus on air pollution control in many Asian countries is also contributing to the growth of the market, as it is a major contributor to the increasing prevalence of asthma in the region.
Key growth strategies adopted by companies operating in the global asthma drugs market include mergers and acquisitions, collaborations and partnerships, and the development of new and innovative asthma drugs. Mergers and acquisitions have been a common strategy for companies looking to expand their product portfolios and increase their market share.
For example, GlaxoSmithKline’s acquisition of Novartis’s asthma and allergy portfolio in 2015 helped the company to become a leader in the global asthma drugs market.
Companies are also collaborating and partnering with other firms to develop new and innovative asthma drugs. For example, AstraZeneca has partnered with the National Heart, Lung, and Blood Institute to develop new drugs for the treatment of asthma.
Additionally, companies are investing in research and development to develop new drugs and treatments for asthma, including biologics and immune-based therapies. The focus on developing more effective and personalized treatments for asthma is expected to drive the growth of the market in the coming years.
Some of the biggest companies operating in the global asthma drugs market are AstraZeneca, GlaxoSmithKline, Merck & Co., Novartis, Pfize, Roche, Sanofi, Teva Pharmaceutical Industries, Abbvie, Boehringer Ingelheim, Eli Lilly and Company, Mundipharma, Mylan N.V., Sunovion Pharmaceuticals Inc, Takeda Pharmaceutical Company, and many more.
By Drug Type
By Mode of Administration
The asthma drugs market is estimated to expand at a CAGR of 5.6% from 2023 to 2032.
The asthma drugs market size was estimated to be US$ 23.32 Billion in 2022.
The growing number of asthma patients is driving demand for effective asthma drugs, while technological advancements have led to the development of more efficient and effective drugs.
The corticosteroids type is the fastest-growing segment of the global asthma drug market.
The fastest-growing mode of administration in the market is the liquid. This is due to the increasing demand for liquid formulations, particularly for children and elderly patients who may have difficulty swallowing pills or using inhalers.
The fastest-growing market for asthma drugs is the Asia Pacific region, due to the increasing prevalence of asthma and the growing awareness about the availability of treatments in countries such as China, India, and Japan.
AstraZeneca, GlaxoSmithKline, Merck & Co., Novartis, Pfize, Roche, Sanofi, Teva Pharmaceutical Industries, Abbvie, Boehringer Ingelheim, Eli Lilly and Company, Mundipharma, Mylan N.V., Sunovion Pharmaceuticals Inc and Takeda Pharmaceutical Company are the top players in this market.
The largest mode of administration segment in the paclitaxel injection market based on end-users is inhalers.
Copyright © 2023 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved